tbuckley/cabot-search huggingface dataset:
Cyclophosphamide To Treat Patients with Scleroderma Lung Disease
Journal: Annals of Internal Medicine (2000)

Summaries for Patients20 June 2000Cyclophosphamide To Treat Patients with Scleroderma Lung DiseaseSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-12-200006200-00044 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Scleroderma is a disease of unknown cause that produces fibrosis (hardening or scarring) of the connective tissue in the skin, blood vessels, and internal organs. This results in a tight, shiny appearance of the skin and potentially life-threatening abnormalities of the lungs, heart, kidneys, and digestive tract. Scleroderma lung disease is difficult to treat. Lung inflammation (alveolitis) occurs before lung scarring (fibrosis). Cyclophosphamide is a drug that decreases inflammation; therefore, it may be useful in treating patients with scleroderma lung disease.Why did the researchers do this particular ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis.” It is in the 20 June 2000 issue of Annals of Internal Medicine (volume 132, pages 947-954). The authors are B. White, W.C. Moore, F.M. Wigley, H.Q. Xiao, and R.A. Wise.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis Barbara White , Wendy C. Moore , Fredrick M. Wigley , Hui Qing Xiao , and Robert A. Wise Metrics 20 June 2000Volume 132, Issue 12Page: 947KeywordsBiopsyBreathingCyclophosphamideDrugsLungsPneumoniaPulmonary functionRespiratory system proceduresSclerodermaUrinary tract infections Issue Published: 20 June 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
Authors: Swee Y. Sharp, Kathy Boxall, Martin Rowlands, Chrisostomos Prodromou, S. Mark Roe, Alison Maloney, Marissa Powers, Paul A. Clarke, Gary Box, Sharon Sanderson, Lisa Patterson, Thomas P. Matthews, Kwai-Ming J. Cheung, Karen Ball, Angela Hayes, Florence Raynaud, Richard Marais, Laurence Pearl, Sue Eccles, Wynne Aherne, Edward McDonald, Paul Workman
Journal: Cancer Research (2019)

The editors were notified that in the original version of this article (1), the GAPDH and Phospho ERK1/2 Western blot bands were inadvertently inserted into Fig. 3A, leading to duplication errors. A review of the original research records by the editors verified that the original scanned images represent the experiments described in the article. The error has been corrected in the latest online PDF version of the article. The authors regret this error.
VIDEO-DIGEST 2008: Preliminary programme - programme préliminaire
Journal: Endoscopy (2008)

Video-Digest is the annual post-graduate course of the French Society of Digestive Endoscopy (SFED). It includes a full day of live video demonstration (in high definition format) and one day of workshops and interactive sessions. This course is linked to the post-graduate course (annual seminar) of the French Society of Gastroenterology (SNFGE).
Mandatory continuing medical education
Authors: R. W. Howard
Journal: JAMA (1976)

The American Medical Association supports the principle of continuing medical education strongly, but it recommends that such education be on a<i>voluntary</i>basis (Resolution 6, adopted, House of Delegates, 124th Annual Convention, June 1975). Nevertheless, medical practice acts in 15 states give the state board of medical examiners in each of them authority to require physicians to produce evidence of continuing medical education as a condition for reregistration of the license to practice medicine. Is the public (or its representatives) being deluded by such legislation? The purpose of such mandatory continuing medical education, and the motivation behind such legislation is not always clear. Perhaps it is felt that more continuing medical education, or at least the documentation of physician participation in such activities, will result in competence when physicians provide health care. The question of whether continuing medical education should be voluntary or mandatory is difficult to answer. Certainly, consensus
Twenty-Fourth Annual Report of the State Board of Health of Massachusetts.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE AMERICAN MEDICO-PSYCHOLOGICAL ASSOCIATION.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2617: Inhibition of Secretory Phospholipase A <sub>2</sub> Activity Attenuates Acute Cardiogenic Pulmonary Congestion Induced by Isoproterenol Infusion in Mice with Post-Myocardial Infarction
Authors: Ken-ichi Kawabata, Tsuyoshi Kobayashi, Yousuke Watanabe, Kazuhiro Watanabe, Toshiaki Yano, Ryota Sato, Yukio Saito, Kazuto Nakamura, Kiyotaka Kugiyama
Journal: Circulation (2008)

Several types of secretory phospholipase A 2 (sPLA 2 ) are expressed in airway epithelial cells and alveolar inflammatory cells, yielding various eicosanoids that might cause pulmonary edema. This study examined whether inhibition of sPLA 2 activity attenuates acute cardiogenic pulmonary congestion in mice. Acute cardiogenic pulmonary congestion in 10-week-old male C57BL/6J mice was induced by continuous intravenous infusion of isoproterenol (ISP) (10 mg/kg/hr) at 2 weeks after the creation of myocardial infarction by left coronary artery ligation. Just before ISP infusion, a single intraperitoneal injection of 100 mg/kg of LY374388 (LY), a prodrug of LY329722 that is a specific inhibitor of activity of all sPLA 2 , or vehicle was administered. Arterial systolic pressure, heart rate, and LV end-diastolic pressure were comparably increased after ISP in both LY-mice and vehicle-mice. Also, lung expression levels of mRNA and protein of group V and X sPLA 2 were comparably increased from baseline by 3 ~ 5-fold in both groups of mice. sPLA 2 activity in lung tissue after ISP was increased from baseline by 5-fold in vehicle-mice, while the activity was not detected in LY-mice. In isolated neutrophils, incubation with LY329722 inhibited the respiratory burst and migration in response to fMLP or C5a by 40~50%. LY significantly reduced the lung-to-body weight ratio after ISP (71% of vehicle-mice) and attenuated alveolar neutrophil accumulation based on the lung histology (56% of vehicle-mice). Using the Evans Blue extravasation method, pulmonary vascular permeability was suppressed in LY-mice (Evans Blue content in lung; 66% of vehicle-mice). The lung content of thromboxane A 2 and leukotriene B 4 was increased in both groups, but was lower in LY-mice (71% and 64% of vehicle-mice, respectively). In Kaplan-Meyer analysis, the survival rate during the 12hr ISP infusion was higher in LY-mice than vehicle-mice (p &lt; 0.01, n = 15 mice per group). Similar results were obtained with another inhibitor of sPLA 2 activity, para -bromophenacyl bromide. Inhibition of sPLA 2 activity suppressed acute cardiogenic pulmonary edema, and sPLA 2 inhibition may have therapeutic value in acute cardiogenic pulmonary congestion.
JAMA Pediatrics
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Shannon Sparenga, Nicole Balin, Miriam Cintron, Paul Ruich, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamczyk, Stephanie Alden, Jan Beckmeyer, Mary Clavey, Paula Coerver-Connolly, Roya Glitman, Laura Khatiblou, Donna King, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Lenette Gardner-Gullens, Fanny Brown, Paul Frank, Peter Kim, Rachell Lozano, Michaela Mark, Kathryn Muskovich, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Will English, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Joshua Bird, Karen Bucher, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Preeti Malani, Deanna Bellandi, Jim Periodical, Thomas Easley Vice, Brian Shields, Monica Smith, Jeffery Bonistalli Manager, Kathy Russell, Mirna Monal, Tim Melroy, Thalia Moss, Mike Harvey, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, David Baum, Rebecca Haas, Christine Hearne, Irma Lara, Ron Marketing, Paul Gee, Matt Herron, Elizabeth Solaro, Geoffrey Flick Managers, Rick Bell, Lindsay Dawson, Michael Mcgraw, Sara Nagy, Romando Rossini, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sean O'donnell, Sue Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Scott Curl, Diane Darnell, Colleen Kelly, Chris Meyer, Jaye Mize, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Tiffany Jones, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Maria Nienhaus, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Dimitri Christakis, Washington Joffe, Ron Keren, Debra Palazzi, Suzanne Shuey, Samir Shah, Howard Bauchner, Frederick Rivara, Joyce Lee, Ann Arbor, Jay Berry, Cherrie Boyer, San Francisco, Maria Britto, John Campo, Aaron Carroll, Indiana Frank, Joseph Chaloupka, Mitchell Cohen, Kathleen Janz, Iowa City, Terry Klassen, Michigan Michelle, Huckaby Lewis, Aaron Milstone, Shawn Rangel, Martha Sola-Visner, Jean-Claude Carel, Shabir Madhi, Ben Marais, Frank Oberklaid, Susan Sawyer, Joan-Carles Surís
Journal: JAMA Pediatrics (2015)
Endoscopic ultrasound
Authors: J.-W. Poley
Journal: Endoscopy (2009)

More than 200 abstracts presented at DDW 2009 attested to the continuing development of endoscopic ultrasound (EUS). Furthermore, EUS continues to evolve from a mere diagnostic modality to a mature endoscopic technique with increasing emphasis on interventional features. This evolution is also demonstrated by the growing number of abstracts dealing with quality and safety. Due to space constraints, only 20 abstracts can be reviewed. In my selection I have tried to incorporate abstracts on those issues that gastroenterologists and endoscopists frequently encounter in daily practice. However, I would like to encourage readers to browse through the many very interesting abstracts that have been published.
PS 0036-0344
Authors: T Ala-Kokko, P Ohtonen, C Schwebel, J Timsit, A Vesin, S Jamali, R Hamidfar, M Garouste-Orgeas, D Goldgran-Toledano, C Adrie, E Azoulay, M Soares, J Salluh, N Spector, A Boumendil, M Garrouste-Orgeas, D Pateron, P Aegerter, D Somme, T Simon, A Menn, R Masmoudi, A Davido, B Guidet, A Lavrentieva, E Mitka, T Frangia, M Kinigopoulou, M Bitzani, J Berkius, T Nolin, C Mårdh, G Karlström, S Walther
Journal: Intensive Care Medicine (2007)
Abortion legislation. Implications for medicine
Authors: A. Milunsky
Journal: JAMA (1982)

AT PRESENT there is congressional activity in Washington, DC, that poses grave danger for the future of medical practice in the United States. It involves the desire of certain politicians to limit the rights of both physicians and patients to decide whether an abortion is required or desirable. Through the use of a proposed constitutional amendment or federal statutes, the federal government could be put in the position of telling physicians what medical procedures they can or cannot perform. This is dissimilar to the ruling that the federal government will not pay for abortions for indigent women (a physician could still provide an abortion although payment is an issue).<sup>1</sup>It is more restrictive than the Food and Drug Administration's regulation of drugs that involves the interstate shipment and sale but not their prescription for specific patients.<sup>2</sup>This new government action could outlaw, or permit the outlawing by states,
Megestrol Acetate in Patients with AIDS and Cachexia
Authors: Michelle H. Oster
Journal: Annals of Internal Medicine (1994)

Objective: To study the effects of a megestrol acetate liquid formulation (800 mg/d) on body weight, body composition, caloric intake, and mental outlook in patients with the acquired immunodeficiency syndrome (AIDS) who had cachexia. Design: Twelve-week, multicenter, randomized, double-blind, placebo-controlled trial. Setting: Multiple clinical centers. Patients: 100 patients with AIDS who had weight loss of 10% or more of ideal body weight were randomly assigned to placebo (n = 48) or megestrol acetate (n = 52). Measurements: Caloric intake, body weight, body composition, and sense of well-being. Results: Most patients receiving megestrol acetate had increased caloric intake resulting in body weight gain (mainly fat mass). From baseline to week 8, the megestrol acetate group increased their daily caloric intake by 608 calories, whereas the placebo group increased intake by 134 calories (difference, 474 calories; 95% CI, −68 to 880 calories). Body weight in the megestrol acetate group increased by 3.86 kg from baseline to week 8, although it decreased by 0.46 kg in the placebo group (difference, 4.32 kg; CI, 2.42 to 6.22 kg). At week 8 in the megestrol acetate group, patients gained 3.68 kg in fat mass and those in the placebo group lost 0.28 kg (difference, 3.96 kg; CI, 2.49 to 5.43 kg). Body water, lean mass, and patient survival were not statistically different between treatment groups. Patients treated with megestrol acetate had an increased sense of well-being when compared with patients who received placebo. Conclusions: This megestrol acetate liquid formulation is well tolerated, increases food intake, results in body weight gain, and improves the sense of well-being in cachectic patients with AIDS.
Journal of Oral Surgery, Chicago
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice
Authors: Scott P. Heximer, Russell H. Knutsen, Xiaoguang Sun, Kevin M. Kaltenbronn, Man-Hee Rhee, Ning Peng, Antonio Oliveira-dos-Santos, Josef M. Penninger, Anthony J. Muslin, Thomas H. Steinberg, J. Michael Wyss, Robert P. Mecham, Kendall J. Blumer
Journal: Journal of Clinical Investigation (2003)
Thyroid-Stimulating Hormone Levels in Children from Chernobyl
Authors: Michael R. Quastel, John R. Goldsmith, Ludmilla Mirkin, Svetlana Poljak, Yehiel Barki, Jackov Levy, Rafael Gorodischer
Journal: Environmental Health Perspectives (1997)

This study assesses parameters of thyroid function in persons who resided in Ukraine, Belarus, and southern Russia and exposed at 0 to 16 years of age to radioiodine contamination from the Chernobyl accident.Six to eight years after the accident a group of 300 young people who had immigrated to Israel were interviewed, underwent physical and ultrasound thyroid examination, and had their serum tested for thyroid-stimulating hormones (TSH), thyroid hormones, thyroglobulin, and antithyroid antibodies.Comparative groups came from areas with high (> 1 Ci/km2) or low (< 1 Ci/km2) 137CS ground contamination.Girls from high contamination areas, when compared to girls from areas with low ground contamination, showed significant upward shifts in levels of serum TSH (p=0.023)although remaining within normal limits.Boys showed no significant differences.There was no evidence for differences in thyroid size or nodularity between the two groups of girls.A working hypothesis is proposed by which the shift in TSH levels in girls from high radiocontamination areas was associated with subclinical radiation damage from environmental radioiodine at the time of the accident.
A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk.
Authors: Toni K. Choueiri, Laurence Albiges, Thomas Powles, Christian Scheffold, Fong Wang, Robert J. Motzer
Journal: Journal of Clinical Oncology (2020)

TPS767 Background: C inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER), and may promote an immune-permissive tumor environment, resulting in enhanced response to immune checkpoint inhibitors. C has shown preliminary clinical activity and tolerability in combination with the PD-1 inhibitor N and as part of a triplet combination with N and the CTLA-4 inhibitor I in pts with aRCC (Nadal et al. ASCO 2018). C is approved for pts with aRCC, and N+I is approved as a combination therapy in pts with previously untreated aRCC of intermediate or poor risk. We present the study design of a phase 3 trial of C+N+I vs N+I in previously untreated pts with aRCC of IMDC intermediate or poor risk (NCT03937219). Methods: This randomized, double-blind, controlled phase 3 study evaluates the efficacy and safety of C+N+I vs N+I in previously untreated pts with IMDC intermediate or poor risk aRCC. Eligible pts are randomized 1:1 to receive C+N+I or N+I in combination with placebo, stratified by IMDC prognostic score and geographic region. Pts receive C (40 mg oral QD) + N (3 mg/kg IV Q3W) x 4 doses + I (1 mg/kg IV Q3W) x 4 doses, followed by C (40 mg oral QD) + N (480 mg IV flat dose Q4W). Control pts receive C-matched placebo and the same treatment regimen for N+I as the experimental arm. N will be administered for a maximum of 2 years. Eligibility criteria include histologically confirmed metastatic or aRCC with a clear cell component, intermediate or poor risk RCC per IMDC criteria, measurable disease per RECIST 1.1, KPS ≥70%, adequate organ and marrow function and age ≥18 years. Exclusion criteria include prior systemic therapy for aRCC and uncontrolled significant illnesses. The primary endpoint is PFS per RECIST 1.1 by BICR; the secondary endpoint is OS. Additional endpoints include ORR, safety, correlation of biomarkers with outcomes, and pharmacokinetics of C in combination with N+I. The first patient was enrolled in June 2019 and enrollment is ongoing. Clinical trial information: NCT03937219.
Another use for vitamin E?
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal